

Amendments to the Claims:

1-25. (Canceled)

26. (Previously Presented) A bispecific tetravalent homodimeric F_v antibody formed by two single-chain F_v monomers, each of said F_v monomers having at least four variable domains, wherein said four variable domains are V_H-A, V_L-A, V_H-B and V_L-B, wherein V_H-A and V_L-A are V_H and V_L domains of an antibody specific for antigen A, respectively, and V_H-B and V_L-B are V_H and V_L domains of an antibody specific for antigen B, respectively;

V_H-A is linked to V_L-B by peptide linker 1, V_L-B is linked to V_H-B by peptide linker 2, V_H-B is linked to V_L-A by peptide linker 3; and

said peptide linker 1 and said peptide linker 3 are a peptide bond or have about 1 to about 10 amino acids; and said peptide linker 2 has 3 to about 10 amino acids.

27. (Previously Presented) The F_v antibody of Claim 26, wherein said peptide linker 1 and peptide linker 2 have the amino acid sequence GG.

3 28. (Previously Presented) The F_v antibody of Claim 26, wherein said peptide linker 2 comprises the amino acid sequence GPGGS.

4 29. (Previously Presented) The F_v antibody of Claim 26, wherein the antibody is bispecific for human CD3 and CD19.

30-31. (Canceled)